BEGIN:VCALENDAR PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN VERSION:2.0 BEGIN:VEVENT DESCRIPTION:Novel conjugates have become one of the most competitive and r apidly evolving areas in the precision oncology landscape. Companies are looking beyond traditional ADCs towards novel mechanism of action payload s and differentiated targeting formats for overcoming drug resistance\, i mproved therapeutic windows and to make an impact in cancers which don’t respond to traditional ADCs\, as well as the exploration of non-oncology indications.\n\nThe 5th Novel Conjugates Summit is the industry’s only de dicated meeting for an insider view into which novel approaches are curre ntly being explored\, what benefit each approach has and the directions t he space is heading.\n\nAttendees gain valuable competitive insight into emerging technologies\, early data\, and the rationale behind each approa ch\, from established pharma leaders to the newest biotech entrants. Whet her your goal is to benchmark your pipeline\, explore partnership opportu nities\, or stay ahead of fast-moving design trends\, this summit offers a front-row seat to the next wave of conjugate innovation.\n\nURLs:Ticket s: \;https://go.evvnt.com/3359045-2?pid=185 \;Brochure: \;htt ps://go.evvnt.com/3359045-3?pid=185 \;\n\nDate and Time: Tue\, 17 Mar 2026 08:00 - Thu\, 19 Mar 2026 16:00\n\nVenue details: Hotel Commonwealt h\, 500 Commonwealth Avenue\, Boston\, Massachusetts\, 02215\, United Sta tes\n\nCategory: Conferences | Science\, Health &\; Medicine | Pharmac euticals\n\nPrices:Drug Developer Pricing - 3 Day Pass (Workshop Day + Co nference): USD 4397.00\,Drug Developer Pricing - 2 Day Pass (Conference O nly): USD 3099.00\,Academic Pricing - 3 Day Pass (Workshop Day + Conferen ce): USD 3797.00\,Academic Pricing - 2 Day Pass (Conference Only): USD 26 99.00\,Solutions Provider Pricing - 3 Day Pass (Workshop Day + Conference ): USD 5297.00\,Solutions Provider Pricing - 2 Day Pass (Conference Only) : USD 3799.00\n\nSpeakers: Wei He\, Chief Scientific Officer\, Accutar Bi otechnology\, Mahendra Deonarain\, Chief Executive Officer\, Antikor\, Su jiet Puthenveetil\, Director - Antibody Drug Conjugates and Radioconjugat es\, AstraZeneca\, Alice Chen\, Chief Scientific Officer\, Baylink Biosci ence\, Yu-Shin Hsu\, Research Analyst Lead\, Beacon\, Tiffany Thorn\, Chi ef Executive Officer\, BiVictriX Therapeutics\, Michael Alonso\, Scientif ic Co-founder and SVP Research\, Bolt Biotherapeutics\, Nick Yoder\, Exec utive Director\, Dyne Therapeutics\, Joe Nabhan\, Chief Scientific Office r\, K2B Therapeutics Inc.\, Andrea Geist\, Senior Scientist\, PROxAb Shut tle\, Merck\, Lan Xu\, Drug Discovery and Translational Medicine Advisor\ , Polymed Biopharmaceuticals\, Dan Shores\, Patent Attorney\, Rothwell Fi gg\, Lucas Bethge\, Vice President and Group Lead - Oligonucleotide Chemi stry\, Silence Therapeutics\, Garrett Gross\, Director\, Research Innovat ion and Protein Engineering\, Sutro Biopharma\, Dori Thomas-Karyat\, Foun der and Chief Executive Officer\, Synthis Therapeutics\, Inc\, Caitlyn Mi ller\, CEO and Co-Founder\, TwoStep Therapeutics\, Arne Scheu\, Co-Founde r and Chief Executive Officer\, Valink Therapeutics\, Irsyad Khairil\, Co -Founder and Chief Technology Officer\, Valink Therapeutics\, Hong Xin\, Senior Director - New Venture\, Search and Evaluation\, Johnson and Johns on\, Vikas Goyal\, Partner\, Growth Investments\, Longwood Funds\, Carla Bauer\, Director\, Search and Evaluation\, Business Development and Licen sing\, Merck\, Xiaodong Zhang\, Director of Search and Evaluation\, Oncol ogy and Haematology\, Novartis\, Juanjo Cragnolini\, Associate Director\, Search and Evaluation\, Oncology R and D\, Takeda Pharmaceutical\, Phili p Low\, Presidential Scholar for Drug Discovery and Ralph C. Corley Disti nguished Professor of Chemistry Purdue University\, Purdue University\n DTEND:20260319T160000 DTSTAMP:20260512T233953Z DTSTART:20260317T080000 LOCATION:Hotel Commonwealth\, 500 Commonwealth Avenue \, Boston\, Massach usetts\, 02215\, SEQUENCE:0 SUMMARY:Novel conjugates have become one of the most competitive and rapid ly evolving areas in the precision oncology landscape. Companies are look ing beyo... UID:bad49362-40e5-454d-8568-d5cdf9ce6bb6 END:VEVENT END:VCALENDAR